StockData

Alnylam Pharmaceuticals vs Sarepta Therapeutics

ALNY and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and SRPT compare

Alnylam Pharmaceuticals is the larger company, worth 11 times as much as Sarepta Therapeutics ($22.1B against $2.0B).

Sarepta Therapeutics scores higher on the StockData Score (12 against 7 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYSRPT
Size and price
Market cap$22.1B$2.0B
Share price$165.00$18.62
Change, 1 year−65.7%−20.6%
Change, 5 years−11.9%−79.1%
Beta (5Y)0.881.02
Employees2,500835
StockData Score
Total score712 (better)
Valuation score03 (better)
Growth score11
Performance score13 (better)
Health score55
Dividend score00
Valuation
P/S–1.0×
P/B6.1×1.3× (better)
P/FCF–24.0×
FCF yield–4.2%
Fair value–$109.03
Margin of safety–82.9%
Growth
Revenue growth (TTM)–−20.4%
Revenue growth, 5Y average49.8% (better)32.4%
Net income growth (TTM)2137%–
Profitability
Operating margin–−7.3%
Net margin–−6.9%
FCF margin–4.1%
Return on equity127% (better)−9.3%
Return on invested capital–−16.8%
Financial health
Debt / equity0.000.00
Current ratio2.484.42 (better)
Altman Z-score2.75 (better)−0.17
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.8%102%
Held by insiders0.49%5.9%
Insider net buying, 12 months−$43.6M−$417K (better)
Short interest, % of float5.8%22.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.